Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.39 |
| ▸ | BCHE | P06276 | 5/20 | 0.38 |
| ▸ | ACHE | P22303 | 5/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14174877 | 0.84 | NPC1 (0.43) | NPC1GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL14174871 | 0.83 | NPC1 (0.62) | NPC1GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL14393578 | 0.82 | GNAI3 (0.50) | NPC1GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL26375593 | 0.80 | NPC1 (0.49) | NPC1GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL12876362 | 0.79 | EPHX2 (0.46) | NPC1GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL31749431 | 0.78 | GNAI3 (0.58) | NPC1GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL8252575 | 0.76 | ALDH1A1 (0.41) | NPC1ALDH1A1ITGB3ITGA2B | |
| SCHEMBL12536206 | 0.76 | ALDH1A1 (0.43) | NPC1GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL18232473 | 0.74 | CPN1 (0.47) | NPC1GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL25075447 | 0.74 | NPC1 (0.41) | NPC1GNAI3GNAO1GNAI1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | NPC1 1789/4885GNAI3 3092/4885GNAO1 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.